These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29131034)

  • 1. Clinical Trial and Registry Data.
    Gooderham M; Papp K
    Curr Probl Dermatol; 2018; 53():15-27. PubMed ID: 29131034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse Reactions to Biologics in Psoriasis.
    Lockwood SJ; Prens LM; Kimball AB
    Curr Probl Dermatol; 2018; 53():1-14. PubMed ID: 29131033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of biologics in psoriasis.
    Kamata M; Tada Y
    J Dermatol; 2018 Mar; 45(3):279-286. PubMed ID: 29226369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologics and Psoriasis: The Beat Goes On.
    Kim HJ; Lebwohl MG
    Dermatol Clin; 2019 Jan; 37(1):29-36. PubMed ID: 30466686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry.
    Strober B; Karki C; Mason M; Guo N; Holmgren SH; Greenberg JD; Lebwohl M
    J Am Acad Dermatol; 2018 Feb; 78(2):323-332. PubMed ID: 29051036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Data on the safety of psoriasis therapies.
    Leonardi CL
    Semin Cutan Med Surg; 2014 Jun; 33(4 Suppl):S73-5. PubMed ID: 25268600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a.
    Leonardi CL
    Semin Cutan Med Surg; 2016 Jun; 35(4 Suppl 4):S74-7. PubMed ID: 27551698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A safety review of recent advancements in the treatment of psoriasis: analysis of clinical trial safety data.
    Kolli SS; Kepley AL; Cline A; Feldman SR
    Expert Opin Drug Saf; 2019 Jun; 18(6):523-536. PubMed ID: 31046481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The TNF/IL-23/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment.
    Ten Bergen LL; Petrovic A; Krogh Aarebrot A; Appel S
    Scand J Immunol; 2020 Oct; 92(4):e12946. PubMed ID: 32697374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The status of biologic therapies in the treatment of moderate to severe psoriasis.
    Menter A
    Cutis; 2009 Oct; 84(4 Suppl):14-24. PubMed ID: 19916298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guselkumab for the treatment of moderate-to-severe plaque psoriasis.
    Yang EJ; Sanchez IM; Beck K; Sekhon S; Wu JJ; Bhutani T
    Expert Rev Clin Pharmacol; 2018 Apr; 11(4):333-344. PubMed ID: 29478344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biologics. New drugs, new adverse reactions].
    Prinz JC
    Hautarzt; 2010 Aug; 61(8):668-75. PubMed ID: 20585746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of the inclusion/exclusion criteria and primary endpoints in pivotal trials of biologics and small oral molecules for the treatment of psoriasis.
    Hsu SH; Tsai TF
    Expert Rev Clin Pharmacol; 2020 Mar; 13(3):211-232. PubMed ID: 32167790
    [No Abstract]   [Full Text] [Related]  

  • 14. Severe and acute complications of biologics in psoriasis.
    Oussedik E; Patel NU; Cash DR; Gupta AS; Feldman SR
    G Ital Dermatol Venereol; 2017 Dec; 152(6):586-596. PubMed ID: 28895664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-immune functions of inflammatory cytokines targeted by anti-psoriatic biologics: a review.
    Lee TL; Tsai TF
    Inflamm Res; 2022 Feb; 71(2):157-168. PubMed ID: 34981130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors.
    Dong J; Goldenberg G
    Cutis; 2017 Feb; 99(2):123-127. PubMed ID: 28319618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of anti-IL-17/23 biologics-induced interstitial pneumonia in patients with psoriasis.
    Miyagawa H; Hara H; Araya J; Minagawa S; Numata T; Umezawa Y; Asahina A; Nakagawa H; Kuwano K
    PLoS One; 2021; 16(1):e0245284. PubMed ID: 33411857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of tumor necrosis factor-α inhibitors in psoriasis: a narrative review.
    Semble AL; Davis SA; Feldman SR
    Am J Clin Dermatol; 2014 Feb; 15(1):37-43. PubMed ID: 24281790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologics in pediatric psoriasis - efficacy and safety.
    Dogra S; Mahajan R
    Expert Opin Drug Saf; 2018 Jan; 17(1):9-16. PubMed ID: 29022425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Side effects of biologic therapies in psoriasis].
    Altenburg A; Augustin M; Zouboulis CC
    Hautarzt; 2018 Apr; 69(4):290-297. PubMed ID: 29568996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.